Heather McArthur, MD, describes how the 2025 ASCO Annual Meeting brought exciting advances in the metastatic breast cancer space. In PD-L1-positive triple-negative breast cancer, sacituzumab govitecan ...

An exceptional range of practice-changing advancements in metastatic breast cancer across all subtypes were presented at ASCO 2025 and are discussed by Dr Ann Partridge of the Dana-Farber Cancer ...

AI innovations, such as the ASCO Guidelines Assistant, enhance evidence-based decision-making by providing quick access to ...

When considering a sequence of therapy for a patient with metastatic breast cancer, oncologists rely heavily on clinical trial data. Sometimes, however, clinical trial data may not be as reliable as ...

Integrative oncology combines standard cancer treatments with complementary therapies to manage symptoms and improve ...

Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with ...

or on the link below. The art of sequencing therapy in the management of breast cancer is a multifaceted challenge that demands the careful integration of clinical trial data, real-world evidence, and ...

Current guidelines for the management of human epidermal growth factor receptor 2 (HER2)-positive disease focus on optimal disease control with limited toxicity by combining sequential HER2-targeted ...

Fig 1. Summary of key guideline recommendations. ADT, androgen deprivation therapy; ARPI, androgen receptor pathway inhibitor; C, conditional; CRPC, castration ...